Apollo Hospitals Enterprise Limited (APOLLOHOSP) AI Stock Analysis

• Market Cap: ₹1.13T
• Dividend Yield: 0.24%
• Average Volume (3M): 12.88K
• Price to Earnings (P/E): 71.7
• Beta (1Y): 0.99
• Revenue Growth: 14.31%
• EPS Growth: 51.71%
• Country: IN
• Employees: 83,147
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 30.10
• Shares Outstanding: 143,784,650
• 10 Day Avg. Volume: 4,618
• 30 Day Avg. Volume: 12,875
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹8,165.71
• Price Target Upside: 3.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 73 Outperform
• Price Target: ₹8,706.00 ▲(10.47% Upside)

Apollo Hospitals' strong financial performance and positive technical indicators are offset by a high valuation, suggesting the stock may be overvalued. The absence of earnings call data and corporate events limits additional insights.

Apollo Hospitals Enterprise Limited Business Overview & Revenue Model

Company Description

Apollo Hospitals Enterprise Limited is a leading healthcare provider in India, renowned for its comprehensive range of medical services. Established in 1983, the company operates a network of hospitals, pharmacies, and primary care centers across the nation. Apollo Hospitals is known for its advanced medical facilities, cutting-edge technology, and a team of skilled healthcare professionals, offering services in various specialties including cardiology, oncology, orthopedics, and more.

How the Company Makes Money

Apollo Hospitals Enterprise Limited generates revenue through multiple streams. The primary source is its hospital services, which include patient care, surgeries, diagnostics, and specialized medical treatments. Additionally, the company earns income through its extensive chain of pharmacies, offering pharmaceutical products and health-related consumer goods. Apollo also benefits from its health insurance partnerships and corporate health services, providing wellness programs and preventive care. Furthermore, the company has ventured into telemedicine, expanding its reach and accessibility, which also contributes to its revenue. Strategic collaborations with international healthcare institutions and investments in healthcare technology further enhance its earnings potential.

Apollo Hospitals Enterprise Limited Financial Statement Overview

Summary

Apollo Hospitals demonstrates strong financial performance with robust revenue growth, improved profitability, and efficient cash flow management. The balance sheet is stable, though debt management remains a focus area.

Income Statement

Apollo Hospitals shows strong revenue growth with a significant increase in total revenue over the past year. The gross profit margin is healthy, indicating efficient cost management. The net profit margin has improved, demonstrating increased profitability. Both EBIT and EBITDA margins are robust, reflecting effective operations and earnings before interest, taxes, depreciation, and amortization.

Balance Sheet

The company's balance sheet reflects a stable financial position with a reasonable debt-to-equity ratio, suggesting manageable leverage. The equity ratio indicates a strong capital structure. The return on equity shows good profitability from shareholders' investments, though there is room for improvement.

Cash Flow

Apollo Hospitals maintains strong operating cash flow, which covers net income well, indicating efficient cash conversion. The free cash flow growth rate is commendable, although the capital expenditures have increased, impacting free cash flow. The company shows effective cash management to support operations and future investments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	211.46B	217.94B	190.59B	145.36B	166.12B	104.68B
Gross Profit	85.48B	69.57B	34.88B	69.63B	80.38B	47.84B
EBITDA	30.71B	32.22B	24.02B	25.57B	21.39B	12.42B
Net Income	13.10B	14.46B	8.99B	10.56B	8.19B	1.50B
Balance Sheet
Total Assets	0.00	206.57B	167.53B	131.92B	144.28B	114.17B
Cash, Cash Equivalents and Short-Term Investments	29.08B	27.93B	11.89B	10.84B	12.14B	14.23B
Total Debt	0.00	78.64B	53.33B	40.68B	43.32B	41.60B
Total Liabilities	-79.15B	120.05B	94.33B	73.15B	78.96B	66.14B
Stockholders Equity	79.15B	82.12B	69.35B	56.23B	61.97B	46.02B
Cash Flow
Free Cash Flow	0.00	2.16B	7.83B	9.71B	2.49B	9.78B
Operating Cash Flow	0.00	19.29B	19.20B	16.28B	13.77B	12.73B
Investing Cash Flow	0.00	-34.77B	-15.37B	-7.78B	-8.71B	-8.72B
Financing Cash Flow	0.00	16.21B	-3.11B	-7.93B	-6.33B	-3.40B

Apollo Hospitals Enterprise Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7881.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:APOLLOHOSP, the sentiment is Positive. The current price of 7881 is above the 20-day moving average (MA) of 7817.22, above the 50-day MA of 7556.87, and above the 200-day MA of 7035.97, indicating a bullish trend. The MACD of 90.28 indicates Positive momentum. The RSI at 59.25 is Neutral, neither overbought nor oversold. The STOCH value of 52.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:APOLLOHOSP.

Apollo Hospitals Enterprise Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FORTIS	75 Outperform	726.76B	84.09	8.68%	0.10%	14.04%	32.99%
MEDANTA	75 Outperform	370.57B	68.38	14.22%	0.04%	15.42%	10.66%
APOLLOHOSP	73 Outperform	₹1.13T	71.75		0.24%	14.31%	51.71%
METROPOLIS	66 Neutral	106.24B	69.46	10.89%	―	12.86%	10.42%
NH	65 Neutral	369.18B	46.24	21.79%	0.25%	12.09%	-2.79%
MAXHEALTH	55 Neutral	1.12T	98.14	11.47%	0.13%	32.65%	8.86%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%